Newly matched donor-derived CD5 CAR T-cells: Clinical Trials

2 recruiting. 2 Phase 1, 2 Phase 2.

By phase and status

Phase	Trials	Status
Phase 1	2	Recruiting 2
Phase 2	2	Recruiting 2

Follow Newly matched donor-derived CD5 CAR T-cells: new trials by email Literature Review of Newly matched donor-derived CD5 CAR T-cells trials Research Report on Newly matched donor-derived CD5 CAR T-cells

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies Autologous CD5 CAR T-cells, Previous stem-cell transplantation (SCT) donor-derived CD5 CAR T-cells, Newly matched donor-derived CD5 CAR T-cells - T-Cell Acute Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, in Relapse	Phase 1 / Phase 2	Recruiting	Beijing GoBroad Hospital	54	2025-07-09	2025-11-26
CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies Autologous CD5 CAR T-cells, Previous stem-cell transplantation (SCT) donor-derived CD5 CAR T-cells, Newly matched donor-derived CD5 CAR T-cells - T-Cell Acute Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, in Relapse	Phase 1 / Phase 2	Recruiting	Beijing GoBroad Hospital	54	2024-06-18	2026-03-10

Conditions studied

Precursor Cell Lymphoblastic Leukemia-Lymphoma (2)  ·  Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (2)

Sponsors

Beijing GoBroad Hospital (2)

Countries

China (2)